# APBA Kısa Özet
The U.S. Food and Drug Administration (FDA) has granted approval to Lisraya (brepocitinib), a once‑daily oral Janus kinase (JAK) and TYK2 inhibitor, marking the first oral therapy specifically indicated for the treatment of dermatomyositis in adults. The decision was based on the results of a pivotal phase 3 randomized, double‑blind, multicenter, placebo‑controlled trial (NCT05437263) that enrolled 241 adult participants with active disease. Over a 52‑week treatment period, patients receiving Lisraya 30 mg daily achieved a higher average Total Improvement Score (TIS), demonstrated better physical function, and showed reduced skin disease activity compared with those receiving placebo. The safety profile was consistent with the known class effects of JAK/TYK2 inhibition, with diarrhea, nausea and upper‑respiratory‑tract infection identified as the most common adverse reactions.
# Çalışma neyi araştırdı?
The trial sought to determine whether oral brepocitinib could provide clinically meaningful improvement in the systemic and cutaneous manifestations of dermatomyositis, a rare autoimmune disease characterized by muscle weakness, skin rash, and systemic inflammation. Specifically, the study evaluated the drug’s ability to increase the Total Improvement Score—a composite endpoint that captures changes across muscle strength, skin disease activity, and patient‑reported outcomes—while also assessing secondary measures such as physical function (e.g., timed‑up‑and‑go, 6‑minute walk) and skin disease activity indices. By comparing these outcomes to a placebo group, the investigators aimed to establish both efficacy and safety of the oral agent in a population that previously had limited oral therapeutic options.
# Yöntem
The phase 3 study was conducted at multiple sites across the United States and enrolled 241 adults meeting established diagnostic criteria for dermatomyositis. Participants were randomly assigned in a 1:1 ratio to receive either Lisraya 30 mg once daily or a matching placebo, with randomization stratified by baseline disease severity. The double‑blind design ensured that neither participants nor investigators were aware of treatment allocation throughout the 52‑week double‑blind period. The primary efficacy endpoint was the change from baseline in the Total Improvement Score at week 52. Key secondary endpoints included validated physical function tests (such as the Health Assessment Questionnaire‑Disability Index) and skin disease activity scores (including the Cutaneous Dermatomyositis Disease Area and Severity Index). Safety assessments comprised regular monitoring of adverse events, laboratory parameters, and vital signs. The trial was registered under NCT05437263 and adhered to Good Clinical Practice guidelines.
# Temel bulgular
Efficacy: Patients receiving Lisraya 30 mg daily demonstrated a statistically significant increase in the mean Total Improvement Score at week 52 compared with placebo, indicating a greater overall clinical response. The magnitude of improvement was consistent across the muscle, skin and patient‑reported components of the composite score. Physical Function: Secondary analyses revealed that the Lisraya group experienced meaningful gains in physical function measures, including faster completion times on the timed‑up‑and‑go test and higher scores on disability indices, relative to placebo. Skin Disease Activity: Reductions in skin disease activity scores were observed in the active treatment arm, suggesting that oral JAK/TYK2 inhibition can effectively target the cutaneous component of dermatomyositis. Safety: The most frequently reported adverse reactions were diarrhea, nausea, and upper‑respiratory‑tract infection. These events were generally mild to moderate in severity and aligned with the known safety profile of JAK/TYK2 inhibitors. No new safety signals emerged during the 52‑week observation period.
# Bulgular ne anlama geliyor?
The trial results indicate that Lisraya provides a clinically relevant benefit for adults with dermatomyositis by improving a composite measure that reflects both systemic muscle involvement and skin disease. The increase in Total Improvement Score suggests that patients experienced a broader disease control than what is typically achieved with existing injectable or intravenous therapies. Improvements in physical function translate to better daily living activities, which is particularly important for a disease that often leads to disability. Moreover, the observed skin benefits address a major source of morbidity and quality‑of‑life impairment in this patient population. Collectively, these findings support the drug’s role as a disease‑modifying oral option.
# Klinik önem
For clinicians, the approval of Lisraya expands the therapeutic armamentarium for dermatomyositis, offering the first oral disease‑modifying agent. The oral route may improve adherence, reduce the need for infusion centers, and simplify treatment logistics, especially for patients living far from specialty clinics. The JAK/TYK2 inhibition mechanism targets cytokine pathways implicated in the pathogenesis of dermatomyositis, providing a rational pharmacologic approach. While the efficacy data are compelling, clinicians must remain vigilant for class‑related adverse events, particularly infections, and should monitor patients for gastrointestinal symptoms. The trial’s 52‑week duration offers reassurance about medium‑term safety, but ongoing pharmacovigilance will be essential to capture rare or delayed events.
# Sınırlılıklar
Population Scope: The study enrolled only adults with dermatomyositis; therefore, the efficacy and safety of Lisraya in pediatric patients, in patients with other idiopathic inflammatory myopathies, or in diverse ethnic groups remain unknown. Treatment Duration: Efficacy assessments were limited to a 52‑week period. Long‑term durability of response beyond one year has not been established by the current data set. Corticosteroid Tapering: Although corticosteroid reduction was captured at week 48, the sustainability of steroid‑sparing effects after the double‑blind phase was not evaluated. Safety Data Completeness: The source material provides a truncated adverse‑event profile. While diarrhea, nausea and upper‑respiratory‑tract infection were identified as common, a comprehensive safety summary—including rare serious events—was not available. * Potential Sponsorship Bias: The trial was industry‑sponsored, and while the risk‑of‑bias assessment was rated low, the possibility of subtle bias in study conduct or reporting cannot be entirely excluded.
Overall, Lisraya represents a significant advance for adult dermatomyositis, offering an oral, disease‑modifying option with demonstrated efficacy over a one‑year period. Continued post‑marketing surveillance and additional studies will be needed to define its long‑term role across broader patient populations.